This CME has expired.
For a list of active online CME, please click here.

CME Information

Up to 3 AMA PRA Category 1 Credit(s)™

Release date: August 2009        Valid through: August 2010

Course Material: Online Only

Receiving CME Credit

To receive online CME credit for this activity, read the full activity then click below to complete the post-test and evaluation on freeCME.com. You will be able to print your CME certificate immediately following completion of the post-test and evaluation.

CME Test and Evaluation

Target Audience
This activity is intended for oncologists, and other medical professionals who treat, assess and counsel patients with lung cancer.

Educational Objectives
Following completion of this activity, participants should be able to:

• Discuss the rationale for early second-line treatment of non–small cell lung cancer (NSCLC).
• Discuss advantages and disadvantages of maintenance antibody therapy in NSCLC.
• Assess treatment strategies incorporating early second-line and/ or maintenance protocols for individual patients.
• Assess implications of data on early second-line and maintenance protocols for practice change.

Overview
Non-small cell lung cancer has long been treated with first-line platinum-based chemotherapy for 4 to 6 cycles followed by a break, then second-line treatment upon progression. This CME activity presents new data and discussion of 3 case studies addressing two new approaches that challenge the current paradigm: (1) early second-line chemotherapy and (2) adding targeted antibodies to the chemotherapy followed by a maintenance antibody phase of treatment. Physicians need to be aware of these data and their implications for practice change, and be able to assess the use of early second-line treatment or combination plus maintenance therapy for individual patients.

Program Faculty

Thomas J. Lynch, Jr., MD
Director, Yale Cancer Center, Physician-in-Chief
Smilow Cancer Center at Yale - New Haven, Connecticut

Alan B. Sandler, MD
Division Chief, Hematology/Oncology
Oregon Health and Science University, Portland, Oregon

Panos Fidias, MD
Clinical Director, Center for Thoracic Cancers
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

Nasser H. Hanna, MD
Division of Hematology/Oncology,Indiana University
School of Medicine, Indianapolis, Indiana

Shadia Jalal, MD
Division of Hematology/Oncology Indiana University
School of Medicine, Indianapolis, Indiana

Sponsorship and Accreditation
This CME activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) by InforMEDical Communications, Inc. InforMEDical is accredited by the ACCME to provide continuing medical education for physicians and takes responsibility for the content, quality and scientific integrity of this CME activity.

Credit Designation
InforMEDical designates this continuing medical education activity for up to 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Educational Grant Support
The program is supported by educational grants provided by: Genentech BioOncology and OSI Oncology, and sanofi-aventis, U.S.

Financial Disclosure
Panos Fidias, MD: Honoraria received from Eli Lilly, Genentech, sanofi-aventis. Nasser H. Hanna, MD: Consultant to Celgene, DMC member, Merck; Honoraria received from Eli Lilly; Speakers’ Bureau for Eli Lilly, Genentech. Shadia Jalal, MD: Nothing to disclose. Thomas J. Lynch, Jr., MD: Consultant to AstraZeneca, OSI, Genentech, Roche, Merck, Millennium, ImClone Systems and Bristol-Myers Squibb; Royalties received from Genzyme for EGFR mutation testing. Alan B. Sandler, MD: Consultant to Genentech; Honoraria received from Hofmann-La Roche. InforMEDical staff and writers, editors and program managers who contributed to this program have nothing to disclose. CME review: Rebecca Suk-Heist, MD: Nothing to disclose. Tracey Evans, MD: Consultant to ImClone; Speakers’ Bureau for Genentech and Eli Lilly.

This educational activity may contain discussion of published and/or investigational uses of agents, devices or diagnostics tools that have not been approved for use by the US FDA. The opinions expressed in the activity are those of the authors, and do not reflect those of the industry supporters or CME sponsor. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Participants/readers should appraise the information presented critically and are encouraged to consult appropriate resources for any product, device or diagnostic tool mentioned in this activity.

NEXT > >